- Home
- OCGN vs NEN Comparison
OCGN vs NEN Comparison
Compare OCGN & NEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OCGN
- NEN
- Stock Information
- Founded
- OCGN 2013
- NEN 1977
- Country
- OCGN United States
- NEN United States
- Employees
- OCGN N/A
- NEN N/A
- Industry
- OCGN Biotechnology: Biological Products (No Diagnostic Substances)
- NEN Building operators
- Sector
- OCGN Health Care
- NEN Real Estate
- Exchange
- OCGN Nasdaq
- NEN Nasdaq
- Market Cap
- OCGN 283.3M
- NEN 262.4M
- IPO Year
- OCGN N/A
- NEN N/A
- Fundamental
- Price
- OCGN $1.09
- NEN $73.75
- Analyst Decision
- OCGN Strong Buy
- NEN
- Analyst Count
- OCGN 3
- NEN 0
- Target Price
- OCGN $6.00
- NEN N/A
- AVG Volume (30 Days)
- OCGN 6.6M
- NEN 425.0
- Earning Date
- OCGN 08-01-2025
- NEN 01-01-0001
- Dividend Yield
- OCGN N/A
- NEN 6.49%
- EPS Growth
- OCGN N/A
- NEN 58.97
- EPS
- OCGN N/A
- NEN 4.56
- Revenue
- OCGN $4,522,000.00
- NEN $82,531,485.00
- Revenue This Year
- OCGN N/A
- NEN N/A
- Revenue Next Year
- OCGN N/A
- NEN N/A
- P/E Ratio
- OCGN N/A
- NEN $16.17
- Revenue Growth
- OCGN N/A
- NEN 6.12
- 52 Week Low
- OCGN $0.52
- NEN $68.98
- 52 Week High
- OCGN $1.67
- NEN $84.00
- Technical
- Relative Strength Index (RSI)
- OCGN 54.73
- NEN 50.87
- Support Level
- OCGN $0.99
- NEN $73.02
- Resistance Level
- OCGN $1.18
- NEN $73.44
- Average True Range (ATR)
- OCGN 0.08
- NEN 0.14
- MACD
- OCGN 0.00
- NEN 0.13
- Stochastic Oscillator
- OCGN 54.55
- NEN 75.00
About OCGN Ocugen Inc.
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").
About NEN New England Realty Associates Limited Partnership Depositary Receipts Evidencing Units of Limited Partnership
New England Realty Associates LP is engaged in the business of acquiring, developing, holding for investment, operating and selling real estate. The Partnership owns and operates various residential apartments, condominium units and commercial properties located in Massachusetts and New Hampshire. The company generates revenue from rental income from residential and commercial properties recognized over the term of the related lease. The long-term goals of the Partnership are to manage, rent and improve its properties and to acquire additional properties with income and capital appreciation potential as suitable opportunities arise.